Neumora Therapeutics Inc (NAS:NMRA)

Q1 2025 Neumora Therapeutics Inc Earnings Call Transcript

May 12, 2025 / 08:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Neumora Therapeutics Inc (NMRA) is advancing an industry-leading pipeline targeting novel mechanisms of action for prevalent brain diseases.
The company is on track to deliver topline data for NMRA 511 in Alzheimer's disease agitation by the end of the year.
Neumora Therapeutics Inc (NMRA) has entered into a $125 million debt facility with K2 Health Ventures, strengthening its financial position.
The company's cash equivalents, marketable securities, and the K2 facility are expected to support operations into 2027.
Neumora Therapeutics Inc (NMRA) has a strong intellectual property portfolio with worldwide rights and patents extending into the 2040s.

Negative

Net loss for the first quarter of 2025 was $68 million, an increase from $53.7 million in the same period in 2024.
The company has faced challenges in patient enrollment for its clinical trials, requiring modifications in site selection and patient screening.
There is no interim analysis planned for the ongoing Coastal 2 and 3 studies, which may delay insights into trial progress.
The company acknowledges that many approved medicines in MDD have failed individual phase 3 studies, indicating potential risks in their trials.
Neumora Therapeutics Inc (NMRA) is reliant on achieving successful outcomes in its clinical trials to file an NDA and advance its pipeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NMRA.OQ - Neumora Therapeutics Inc
Q1 2025 Neumora Therapeutics Inc Earnings Call
May 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by.

At this time, all participants are on a listen-only mode.

After the speaker's presentation, there will be a question and answer session.

Please be advised that today's conference is being recorded.

I would now like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations and communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and thank you for joining Numura Therapeutics first quarter 2025 Financial results

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.